{
  "ticker": "FPH",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967927",
  "id": "02967927",
  "pages": 23,
  "price_sensitive": false,
  "date": "20250710",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lng39hkhx79j.pdf",
  "summary": "**Summary of Fisher & Paykel Healthcare ASX Announcement \u2013 Annual Shareholders\u2019 Meeting Notice**  \n\n- **Meeting Details**:  \n  - **Date**: 21 August 2025 (2:00pm NZST).  \n  - **Format**: Hybrid (in-person at Auckland HQ + virtual).  \n  - **Record Date for Voting**: 19 August 2025.  \n\n- **Key Resolutions**:  \n  1. **Director Re-Elections**: Neville Mitchell, Lewis Gradon (CEO), Lisa McIntyre, Cather Simpson.  \n  2. **New Director Election**: Mark Cross (appointed 1 October 2024).  \n  3. **Auditor Remuneration**: Authorization to fix PwC fees.  \n  4. **CEO Equity Grant Approval**: Discretionary long-term variable remuneration (PSRs/Options) worth **$1.27M**, subject to performance hurdles vs. DJUS Medical Equipment & ASX 200 indices.  \n\n- **Material CEO Equity Terms**:  \n  - **Vesting**: 3-year performance period; 50\u2013100% vesting based on TSR outperformance vs. benchmarks.  \n  - **Clawback**: Applies for misconduct or financial misreporting.  \n\n**No material trading or capital markets impacts identified.** (Routine governance update.)  \n\n*Note: Omitted procedural details, director bios, and non-material operational context.*",
  "usage": {
    "prompt_tokens": 7432,
    "completion_tokens": 292,
    "total_tokens": 7724,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T21:54:50.110575"
}